Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology.
about
The influence of locked nucleic acid residues on the thermodynamic properties of 2'-O-methyl RNA/RNA heteroduplexesStable transmission of targeted gene modification using single-stranded oligonucleotides with flanking LNAsAdvanced In vivo Use of CRISPR/Cas9 and Anti-sense DNA Inhibition for Gene Manipulation in the BrainGeneration of Aptamers with an Expanded Chemical RepertoireNMR structure of a kissing complex formed between the TAR RNA element of HIV-1 and a LNA-modified aptamerSynthetic oligonucleotides recruit ILF2/3 to RNA transcripts to modulate splicingBiophysical analysis of triple-helix formation.A rapid synthetic route to conformationally restricted [5,5]-bicyclic nucleoside-amino acid conjugates.Structure and dynamics of the HIV-1 frameshift element RNAA microfluidic-assisted microarray for ultrasensitive detection of miRNA under an optical microscope.Glycoprotein hyposialylation gives rise to a nephrotic-like syndrome that is prevented by sialic acid administration in GNE V572L point-mutant mice.Unrestricted accessibility of short oligonucleotides to RNAIsoenergetic penta- and hexanucleotide microarray probing and chemical mapping provide a secondary structure model for an RNA element orchestrating R2 retrotransposon protein functionComparison of RNA- or LNA-hybrid oligonucleotides in template-switching reactions for high-speed sequencing library preparation.Electroporation and microinjection successfully deliver single-stranded and duplex DNA into live cells as detected by FRET measurements.Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection.Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy.Basic peptide-morpholino oligomer conjugate that is very effective in killing bacteria by gene-specific and nonspecific modes.Chemistry of nucleic acids: impacts in multiple fields.Microparticle-based delivery of oxytocin receptor antisense DNA in the medial amygdala blocks social recognition in female mice.Biophysical studies of DNA modified with conformationally constrained nucleotides: comparison of 2'-exo (north) and 3'-exo (south) 'locked' templatesEnzymatic synthesis of DNA strands containing α-L-LNA (α-L-configured locked nucleic acid) thymine nucleotides.Oligonucleotides and polyribonucleotides: a review of antiviral activity.Comparative crystallization and preliminary X-ray diffraction studies of locked nucleic acid and RNA stems of a tenascin C-binding aptamer.Dynamic microRNA-101a and Fosab expression controls zebrafish heart regenerationA multifaceted FISH approach to study endogenous RNAs and DNAs in native nuclear and cell structures.Nucleic acid therapeutics for hematologic malignancies--theoretical considerations.Properties of pseudo-complementary DNA substituted with weakly pairing analogs of guanine or cytosineMicroRNAs as targets for antisense-based therapeutics.Context-dependent differences in miR-10b breast oncogenesis can be targeted for the prevention and arrest of lymph node metastasisConformationally rigid nucleoside probes help understand the role of sugar pucker and nucleobase orientation in the thrombin-binding aptamerOvercoming biological barriers to in vivo efficacy of antisense oligonucleotides.Nucleic acid-based fluorescent probes and their analytical potential.Pharmacological strategies for lowering LDL cholesterol: statins and beyond.Improvement of DNA recognition through molecular imprinting: hybrid oligomer imprinted polymeric nanoparticles (oligoMIP NPs).Targeting VEGF with LNA-stabilized G-rich oligonucleotide for efficient breast cancer inhibition.Sequence motifs associated with hepatotoxicity of locked nucleic acid--modified antisense oligonucleotides.Systematic analysis of enzymatic DNA polymerization using oligo-DNA templates and triphosphate analogs involving 2',4'-bridged nucleosides.Functional correction by antisense therapy of a splicing mutation in the GALT geneRational Design of Short Locked Nucleic Acid-Modified 2′-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro.
P2860
Q24812616-8CB2E119-824E-4EAA-8CE0-4AEB610B4036Q24816245-FC8A5120-A2D5-4901-8521-CB806C026F6BQ26770355-3D420DA3-130F-4B80-A2B6-B397B521C4AEQ26782794-19A7500C-79DB-4F01-8274-525773C5B968Q27647789-E9FAC03A-5D14-4A5A-BF47-62710F97143DQ28830393-C6E2E7B8-088C-4EDE-82D7-182A2BFC8F13Q33329992-CDA3E77A-6C32-48D8-BA8C-FD6942F51B94Q33359427-F5144375-2C18-4C9F-96CC-378020C6A959Q33873954-293904E3-FEE6-4123-9C2D-A3972CEA4308Q33883810-68D0BC60-1530-4685-8E21-E7517DF185C2Q34130746-CE0117A3-7FFD-4980-A3A3-F0894ECACF0CQ34366583-6AC85999-4F23-4729-AB81-154F510CC749Q34588002-D898D345-BFA1-4B99-B829-ECF14E9EA703Q35002499-59FA8304-D860-4D5D-9E5C-FEE3DB079E75Q35154985-BB0429C5-401F-4EE2-9F58-A1C425B299E8Q35159206-63608B6E-F3B2-4120-AF21-D128BB369039Q35237068-D266BFD6-7D6F-4E8C-8757-BD68FC358B91Q35289367-600AE089-A081-4BBE-9267-348B043645F3Q35652657-A7AD96B2-519B-4044-8959-B13099BB2E59Q35721717-AB6C908D-8542-45E9-88A9-F8E3DBE6C06BQ35849958-FD966B71-8B8D-48DF-8F23-489218B52E23Q36012670-23035693-5B83-4148-8F79-B8693BCC7F6DQ36124734-39BE9C67-9D5A-48F5-9603-A6158A005F24Q36459520-AB7E6F48-8354-4658-A03B-7A95988944C7Q36462531-4A56ACD7-F086-4267-BFD2-56CF784FF66FQ36566744-F16D000D-C5DA-492A-97A4-A53886CA1C4BQ36673652-CA4ACEEA-EA81-48E8-8B4D-F77262F03B46Q37014656-3B8362BA-ED6A-4175-A55A-7A8268C277D6Q37032639-3ACAAE55-ABEF-4D64-BE03-FC59E770FF57Q37039800-3779F4FA-D8F2-4066-A7E3-CD69F5BD92D9Q37385856-50AB71D3-08F0-4772-8ACF-5595E5744453Q37419563-30835223-AD46-48AE-A5BF-AF5AA3B1C39CQ37806645-4E60ADFB-3A52-4E05-BEC0-996599364DFBQ37842120-F68198A2-A712-42D0-977A-128E4CAD1382Q38295688-CC87F138-C1DE-46B3-9210-8F416EC818A7Q38299065-2A24C76F-08CD-4BEE-BC5E-8D060CB852DEQ38308838-400E6E0A-6E09-4C8D-9708-6E9E0B4FAB3FQ41174277-FD808FBF-5431-4124-A184-4938B8662284Q42736904-D291CA86-EFC4-49A9-9B7C-6E44D50E252BQ45851717-13467C12-3E60-4932-875E-83196B44F04C
P2860
Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology.
@ast
Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology.
@en
type
label
Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology.
@ast
Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology.
@en
prefLabel
Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology.
@ast
Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology.
@en
P356
P1433
P1476
Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology
@en
P2093
Jan Stenvang Jepsen
Mads D Sørensen
P304
P356
10.1089/1545457041526317
P577
2004-01-01T00:00:00Z